BDSX Biodesix

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture

LOUISVILLE, Colo., April 09, 2026 (GLOBE NEWSWIRE) -- Biodesix is proud to announce that it has earned the prestigious 2026 USA TODAY Top Workplaces award. The award honors organizations with 150+ employees that have created exceptional, people-first cultures. The winners are determined by direct employee feedback captured through a confidential survey conducted by , the HR research and technology company behind the program since 2006.

The results are calculated based on the employees’ responses to statements about Workplace Experience Themes—themes which are proven indicators of high performance. Biodesix excelled in employee engagement due to high rankings in the following areas:

  • teammates are motivated to do their absolute best work,
  • the work makes teammates feel they are part of something meaningful, and
  • teammates feel cared about and are enabled to work at their full potential.



“Earning this honor once is meaningful. Earning it three years in a row reflects who we are at our core — a team built on trust, collaboration, growth, and shared ownership of results. What makes this recognition especially powerful is that it comes directly from our team members and their experience at Biodesix,” said Scott Hutton, CEO, Biodesix. “I am proud of our team and the culture we continue to build together, one that empowers high performance and holds us accountable for delivering real-life impact for patients.”

"Earning a USA TODAY Top Workplaces award is a testament to an organization’s credibility and commitment to a people-first culture," said Eric Rubino, CEO of Energage. "This award, driven by real employee feedback, is more than just a recognition — it’s proof that your employees believe in the organization and its leadership. Job seekers and customers look for this trusted badge of credibility and excellence. It signals a company that values its people — that kind of culture resonates in today’s competitive market."

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts

Media:

Natalie St. Denis, Director Corporate Communications



(720) 925-9285

Investors:

Chris Brinzey, Partner, ICR



(339) 970-2843



EN
09/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Biodesix Recognized as a Top Workplace for Third Consecutive Year Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture LOUISVILLE, Colo., April 09, 2026 (GLOBE NEWSWIRE) -- Biodesix is proud to announce that it has earned the prestigious 2026 USA TODAY Top Workplaces award. The award honors organizations with 150+ employees that have created exceptional, people-first cultures. The winners are determined by direct employee feedback captured through a confidential survey conducted by , the HR research and technology company behind the pr...

 PRESS RELEASE

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting N...

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing LOUISVILLE, Colo., April 06, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that the company will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, from April 17 ...

 PRESS RELEASE

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validati...

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations LOUISVILLE, Colo., March 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the . This milestone strengthens the clinical foundation for Nodify CDT® tests as a critical decision-support tool in the early detection of ...

 PRESS RELEASE

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Hig...

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "B...

 PRESS RELEASE

Biodesix to Participate in Upcoming Investor Conferences

Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participate in two upcoming investor conferences: TD Cowen's 46th Annual Health Care ConferenceFireside Chat Date: Tuesday, March 3, 2026Fireside Chat Time: 2:30 PM ETLocation: Boston, MA Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date: Wednesday, March 11, 2026Fireside Chat Time: 12:00 PM ETLocation: Miami, FL The fireside chats will be...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch